The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders

J Allergy Clin Immunol. 2023 Mar;151(3):595-606. doi: 10.1016/j.jaci.2023.01.007.

Abstract

Continuing insight into the molecular mechanisms of atopic disorders has enabled the development of biologics to precisely target these diseases. Food allergy (FA) and eosinophilic gastrointestinal disorders (EGIDs) are driven by similar inflammatory molecular mechanisms and exist along the same atopic disease spectrum. Therefore, many of the same biologics are being investigated to target key drivers of mechanisms shared across the disease states. The enormous potential of biologics for the treatment of FA and EGIDs is highlighted by the significant increases in the number of ongoing clinical trials (more than 30) evaluating their use in these disease states, as well as by the recent US Food and Drug Administration approval of dupilumab for the treatment of eosinophilic esophagitis. Here we discuss past and current research into the use of biologics in FA and EGIDs and their potential role in improving treatment options in the future, with the need to have biologics widely clinically available.

Keywords: Food allergy; biologics; eosinophilic colitis; eosinophilic enteritis; eosinophilic esophagitis; eosinophilic gastritis; eosinophilic gastrointestinal disorders; oral immunotherapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Biological Products*
  • Child
  • Enteritis*
  • Eosinophilia
  • Eosinophilic Esophagitis*
  • Food Hypersensitivity*
  • Gastritis
  • Humans
  • United States

Substances

  • Biological Products

Supplementary concepts

  • Eosinophilic enteropathy